Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines

Cancer Letters

Volumn 277, Issue 2, 2009, Pages 218-226

  Vogl, Ursula Maria ^a   Berger, Walter ^b   Micksche, Michael ^b   Pirker, Christine ^b   Lamm, Wolfgang ^a   Pichelmeyer, Oskar ^a   Zielinski, Christoph C ^a   Schmidinger, Manuela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Enzastaurin; Renal cell carcinoma; Sorafenib; Sunitinib; Synergism

Indexed keywords

ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; LY317615 HCL; S6 KINASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; PROTEIN KINASE C; PYRIDINES; PYRROLES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION;

EID: 62749137151     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.013     Document Type: Article

References (38)

1. J. Schroeder (Ed.), Nierenzellkarzinome: Klassifikation, Subtypisierung und prognostische Faktoren, 1998.
2. In: Linehan P.D. (Ed). Cancer: Principles and Practice of Oncology (1993), JB Lippincott, PA
3. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., and Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22 (2004) 454-463
4. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17 (1999) 2530-2540
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., and Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
6. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W., Collins D., Majoor-Krakauer D., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332 (1988) 268-269
7. Krieg M., Haas R., Brauch H., Acker T., Flamme I., and Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19 (2000) 5435-5443
8. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., Cranston D., and Harris A.L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62 (2002) 2957-2961
9. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19 (2000) 6297-6305
10. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13 (2007) 680s-684s
11. Motzer R.J., Hudes G.R., Curti B.D., McDermott D.F., Escudier B.J., Negrier S., Duclos B., Moore L., O'Toole T., Boni J.P., and Dutcher J.P. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J. Clin. Oncol. 25 (2007) 3958-3964
12. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 10 (2004) 6388S-6392S
13. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., and Bukowski R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 125-134
14. Finkenzeller G., Marme D., Weich H.A., and Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 52 (1992) 4821-4823
15. Martiny-Baron G., and Fabbro D. Classical PKC isoforms in cancer. Pharmacol. Res. 55 (2007) 477-486
16. Dekker L.V., and Parker P.J. Protein kinase C-a question of specificity. Trends Biochem. Sci. 19 (1994) 73-77
17. Yoshiji H., Kuriyama S., Ways D.K., Yoshii J., Miyamoto Y., Kawata M., Ikenaka Y., Tsujinoue H., Nakatani T., Shibuya M., and Fukui H. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59 (1999) 4413-4418
18. Xia P., Aiello L.P., Ishii H., Jiang Z.Y., Park D.J., Robinson G.S., Takagi H., Newsome W.P., Jirousek M.R., and King G.L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98 (1996) 2018-2026
19. Keyes K.A., Mann L., Sherman M., Galbreath E., Schirtzinger L., Ballard D., Chen Y.F., Iversen P., and Teicher B.A. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharm. 53 (2004) 133-140
20. Brenner W., Farber G., Herget T., Wiesner C., Hengstler J.G., and Thuroff J.W. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anticancer Res. 23 (2003) 4001-4006
21. Sauma S., Yan Z., Ohno S., and Friedman E. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ. 7 (1996) 587-594
22. Carducci M.A., Musib L., Kies M.S., Pili R., Truong M., Brahmer J.R., Cole P., Sullivan R., Riddle J., Schmidt J., Enas N., Sinha V., Thornton D.E., and Herbst R.S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24 (2006) 4092-4099
23. Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L., Huss K.L., Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J., Musib L., Geeganage S., and Thornton D. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, suppresses growth of human colon Cancer glioblastoma xenografts. Cancer Res. 65 (2005) 7462-7469
24. Podar K., Raab M.S., Zhang J., McMillin D., Breitkreutz I., Tai Y.T., Lin B.K., Munshi N., Hideshima T., Chauhan D., and Anderson K.C. Targeting PKC in multiple myeloma: in vitro in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 109 (2007) 1669-1677
25. Rizvi M.A., Ghias K., Davies K.M., Ma C., Weinberg F., Munshi H.G., Krett N.L., and Rosen S.T. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Ther. 5 (2006) 1783-1789
26. Hanauske A.R., Oberschmidt O., Hanauske-Abel H., Lahn M.M., and Eismann U. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments. Invest. New Drugs 25 (2007) 205-210
27. Hanauske A.R., Eismann U., Oberschmidt O., Pospisil H., Hoffmann S., Hanauske-Abel H., Ma D., Chen V., Paoletti P., and Niyikiza C. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest. New Drugs 25 (2007) 417-423
28. Lee K.W., Kim S.G., Kim H.P., Kwon E., You J., Choi H.J., Park J.H., Kang B.C., Im S.A., Kim T.Y., Kim W.H., and Bang Y.J. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 68 (2008) 1916-1926
29. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., Grigg A., Wolf M., Pfreundschuh M., Tilly H., Raemaekers J., van 't Veer M.B., Milpied N., Cartron G., Pezzutto A., Spencer A., Reyes F., and Dreyling M. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. (2007)
30. Robertson M.J., Kahl B.S., Vose J.M., de Vos S., Laughlin M., Flynn P.J., Rowland K., Cruz J.C., Goldberg S.L., Musib L., Darstein C., Enas N., Kutok J.L., Aster J.C., Neuberg D., Savage K.J., LaCasce A., Thornton D., Slapak C.A., and Shipp M.A. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25 (2007) 1741-1746
31. Moreau A.S., Jia X., Ngo H.T., Leleu X., O'Sullivan G., Alsayed Y., Leontovich A., Podar K., Kutok J., Daley J., Lazo-Kallanian S., Hatjiharissi E., Raab M.S., Xu L., Treon S.P., Hideshima T., Anderson K.C., and Ghobrial I.M. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 109 (2007) 4964-4972
32. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., Grigg A., Wolf M., Pfreundschuh M., Tilly H., Raemaekers J., van 't Veer M.B., Milpied N., Cartron G., Pezzutto A., Spencer A., Reyes F., and Dreyling M. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. 19 (2008) 247-253
33. Rademaker-Lakhai J.M., Beerepoot L.V., Mehra N., Radema S.A., van Maanen R., Vermaat J.S., Witteveen E.O., Visseren-Grul C.M., Musib L., Enas N., van Hal G., Beijnen J.H., Schellens J.H., and Voest E.E. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 13 (2007) 4474-4481
34. Camidge D.R., Gail Eckhardt S., Gore L., O'Bryant C.L., Leong S., Basche M., Holden S.N., Musib L., Baldwin J., Darstein C., Thornton D., Finn R.S., and Britten C.D. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 19 (2008) 77-84
35. Oh Y., Herbst R.S., Burris H., Cleverly A., Musib L., Lahn M., and Bepler G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 1135-1141
36. Sourbier C., Lindner V., Lang H., Agouni A., Schordan E., Danilin S., Rothhut S., Jacqmin D., Helwig J.J., and Massfelder T. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res. 66 (2006) 5130-5142
37. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regulat. 22 (1984) 27-55
38. Keyes K., Cox K., Treadway P., Mann L., Shih C., Faul M.M., and Teicher B.A. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res. 62 (2002) 5597-5602